LDS/Medical Tests/Auria® Biological Breast Cancer Screening Test

Auria® Biological Breast Cancer Screening Test

Breast cancer remains the most common cancer among women worldwide, affecting approximately one in eight women in the United States during their lifetime. Historically, familial history was considered the primary risk factor; however, recent research highlights that a significant proportion of breast cancer patients have no familial predisposition. This revelation has significantly transformed breast cancer screening methodologies, leading to the advent of personalized liquid biopsy technologies. These assays typically analyze blood, saliva, tears, or other body fluids for molecular biomarkers including cell-free DNA (cfDNA), circulating tumor cells (CTCs), exosomes, microRNAs (miRNAs), or tumor-educated platelets.

The Auria® Biological Breast Cancer Screening Test is a proprietary, innovative assay employing tear samples to analyze specific protein biomarkers indicative of early inflammatory changes associated with breast cancer development. Unlike conventional genomic DNA-based tests, Auria® screens for proteins, particularly the S100A8 and S100A9 proteins, elevated in the presence of abnormal breast tissue pathology, thus potentially indicating increased breast cancer risk.

Critically, this test serves as a screening tool and does not provide a definitive diagnosis of breast cancer. Auria® represents the first available at-home breast cancer screening assay, suitable for women aged 30 and older. In clinical validation involving over 2,500 samples, Auria® demonstrated a sensitivity of approximately 91.5% and a specificity of 58%.

  • Early breast cancer risk screening for women aged 30 years and older
  • Supplementary screening method for women with familial breast cancer history
  • Aid in the stratification of breast cancer risk to guide further clinical evaluation and surveillance
A detailed interpretive report indicating expression levels of proteins associated with inflammatory processes (notably S100A8 and S100A9) is provided. Results assist healthcare professionals in identifying individuals at elevated risk who may benefit from additional diagnostic assessments such as mammography, ultrasound, MRI, or genetic testing. Important Note: Positive screening results do not confirm breast cancer diagnosis. Clinical correlation and further diagnostic evaluation are essential.

Not applicable (Results provided as individualized interpretative risk scores)

Protein Microarray (Enzyme-Linked Immunosorbent Assay [ELISA]).

Specific instructions and kits provided by Auria® (auria.care).

Genetic testing for BRCA1 and BRCA2 mutations for hereditary breast cancer risk assessment.
5-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • PLoS One. 2022 Apr 26;17(4):e0267676. [PMID: 35471994]
  • Cancer Genomics Proteomics. 2009 May-Jun;6(3):177-82. [PMID: 19487546]
  • Breast Cancer Res Treat. 2009 Jul;116(1):17-29. [PMID: 19082706]
  • Tears as the Next Diagnostic Biofluid: A Comparative Study between Ocular Fluid and Blood. Appl. Sci. 2022, 12, 2884. https://doi.org/10.3390/app12062884
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login